Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Therapeutics Signs Agreement With NCCTG For Pixantrone Phase II Study
Cell Therapeutics said that the proposed trial design is to test two different dosing schedules of Pixantrone. Patients on the trial are expected to be randomised to receive
Cell Therapeutics said that the proposed trial design is to test two different dosing schedules of Pixantrone. Patients on the trial are expected to be randomised to receive
The FDA Arthritis Drugs Advisory Committee and Drug Safety and Risk Management Committee based their recommendation on a review of data from the Naproxcinod clinical development program, which
Aventis Pharma said that SITE is the first cross-sectional study to assess the prevalence of diagnosed and undiagnosed cases of diabetes and hypertension amongst nearly 20,000 patients visiting
Strides said that Vecuronium is a nondepolarising neuromuscular blocking agent claimed to possess all of the characteristic pharmacological actions of this class of drugs (curariform). Vecuronium is about
Aeterna Zentaris has posted a net loss of $5.9m for the first quarter of 2010, or $0.09 per diluted share, compared to $12.4m, or $0.23 per diluted share,
Zydus Cadila has claimed that with this, it will become the first Indian pharma company to launch its vaccine which will be marketed under the brand name VaxiFlu-S.
RGN-352 is an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tß4, for patients who have suffered an acute myocardial infarction, or AMI or heart
Antares Pharma has posted a net loss of $1.6m for the first quarter 2010, or $0.02 per diluted share, compared to $2.78m, or $0.04 per diluted share, for
Reportedly, preclinical studies have shown that Omeros’ proprietary, fully human, monoclonal MASP-2 antibodies shut down the lectin pathway of the complement system, which is part of the immune
Shire said that the lawsuit results from an abbreviated new drug application (ANDA) filed by Actavis for generic versions of 1mg, 2mg, 3mg and 4mg guanfacine hydrochloride extended